Principles of Translational Science in Medicine
From Bench to Bedside
3rd Edition
Published on 22. July 2021
Book
Hardback
494 pages
978-0-12-820493-1 (ISBN)
Description
Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing number of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics.
New chapters include: Translation in Oncology, Biologicals, and Orphan Drugs. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine and is written by worldwide experts in their respective fields.
New chapters include: Translation in Oncology, Biologicals, and Orphan Drugs. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine and is written by worldwide experts in their respective fields.
More details
Edition
3rd edition
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
All biomedical researchers from preclinical to clinical scientists need to understand and apply translational science in medicine, which applies to scientists in pharmaceutical industry though almost all principles are applicable to device development. Additionally, academic researchers will need the book, as well.
Most major universities offer courses, programs (e.g. master programs) in translational medicine for which the book is ideal as the basic teaching material. It is currently used in courses on pharmaceutical medicine e.g. at Basle University.
Product notice
sewn/stitched
Cloth over boards
Illustrations
105 illustrations (40 in full color); Illustrations
Dimensions
Height: 285 mm
Width: 218 mm
Thickness: 28 mm
Weight
1590 gr
ISBN-13
978-0-12-820493-1 (9780128204931)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
E-Book
07/2021
3rd Edition
Academic Press
€140.00
Available for download
Previous edition
Book
04/2015
2nd Edition
Academic Press
€120.50
Shipment within 15-20 days
Person
Martin Wehling is the Managing Director at the Institute of Experimental and Clinical Pharmacology and Toxicology. Martin Wehling is Director in Clinical Pharmacology at Mannheim Medical Faculty, Mannheim University of Heidelberg, Mannheim, Germany.
Content
Part I: Introduction
1. Introduction and definitions
2. Problems, challenges, and initiatives in translation
Part II. Target identification and validation
3. "Omics? translation: a challenge for laboratory medicine
4. The power of genomics, metabolomics, and other omics for target identification and validation
5. Potency analysis of cellular therapies: the role of molecular assays
6. Translational pharmacogenetics: pharmacogenetically driven clinical decision making
7. Tissue biobanks
8. Animal models: value and translational potency
9. Biomarkers in the context of health authorities and consortia
10. Human studies as a source of target information
11. Target profiling in terms of translatability and early translation planning
Part III. Biomarkers as key elements of successful translation
12. Biomarkers
13. Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy
14. Cardiovascular translational biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development in the digital era
15. Biomarkers in oncology
16. Translational medicine in psychiatry: challenges and imaging biomarkers
Part IV: Early clinical trial design
17. Methodological studies
18. The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?
19. Adaptive trial design
20. Combining regulatory and exploratory trials
21. Accelerating proof of concept by smart early clinical trials
Part V: Toxicology in translation
22. Pharmaceutical toxicology
23. Translational safety medicine
Part VI: Special topics in translation
24. Cancer vaccines: translational strategies
25. Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples
26. Orphan drugs: why is translation so successful?
Part VII: Biostatistics and modelling
27. Translational science biostatistics
28. Computational biology and model-based approaches in translational medicine
Part VIII. Legal aspects and special interest groups
29. Intellectual property and innovation in translational medicine
30. Translational research in the fastest-growing population: older adults
Part IX. Integration and application of translational guidance
31. Translational medicine: the changing role of big pharma
32. Translational science in medicine: putting the pieces together-biomarkers, early human trials, networking, and translatability assessment
33. Learning by experience
1. Introduction and definitions
2. Problems, challenges, and initiatives in translation
Part II. Target identification and validation
3. "Omics? translation: a challenge for laboratory medicine
4. The power of genomics, metabolomics, and other omics for target identification and validation
5. Potency analysis of cellular therapies: the role of molecular assays
6. Translational pharmacogenetics: pharmacogenetically driven clinical decision making
7. Tissue biobanks
8. Animal models: value and translational potency
9. Biomarkers in the context of health authorities and consortia
10. Human studies as a source of target information
11. Target profiling in terms of translatability and early translation planning
Part III. Biomarkers as key elements of successful translation
12. Biomarkers
13. Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy
14. Cardiovascular translational biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development in the digital era
15. Biomarkers in oncology
16. Translational medicine in psychiatry: challenges and imaging biomarkers
Part IV: Early clinical trial design
17. Methodological studies
18. The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?
19. Adaptive trial design
20. Combining regulatory and exploratory trials
21. Accelerating proof of concept by smart early clinical trials
Part V: Toxicology in translation
22. Pharmaceutical toxicology
23. Translational safety medicine
Part VI: Special topics in translation
24. Cancer vaccines: translational strategies
25. Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples
26. Orphan drugs: why is translation so successful?
Part VII: Biostatistics and modelling
27. Translational science biostatistics
28. Computational biology and model-based approaches in translational medicine
Part VIII. Legal aspects and special interest groups
29. Intellectual property and innovation in translational medicine
30. Translational research in the fastest-growing population: older adults
Part IX. Integration and application of translational guidance
31. Translational medicine: the changing role of big pharma
32. Translational science in medicine: putting the pieces together-biomarkers, early human trials, networking, and translatability assessment
33. Learning by experience